Krsnaa Diagnostics profit and loss

Latest FY26

Revenue: ₹773cr+7.8% on FY25
EBITDA: ₹212cr+11.4% on FY25
Net profit: ₹101cr+30.7% on FY25
EPS: ₹31.30+30.2% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	815	773	717	620	487	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	46.7	43.4	25.5	16.8	19.4
	862	816	743	636	507
	182	179	169	141	74.2
	141	140	137	111	74.6
	42.9	34.4	24.7	16.5	7.7
	96.8	90.5	88.3	74.5	53.8
	274	241	221	223	216
	737	686	640	566	426
	218	212	190	144	122
	122	121	102	69.7	68.5
Profit
	125	130	103	70.0	80.2
	125	130	103	70.0	80.2
	24.4	24.4	21.8	10.8	15.0
	3.6	4.5	3.3	2.4	3.1
	27.9	28.9	25.1	13.2	18.1
	−0.1	−0.1	0.0	0.0	0.0
	97.5	101	77.6	56.8	62.1
	97.5	102	77.6	56.8	62.1
	0.2	0.2	0.5	−0.1	0.5
	97.6	102	78.1	56.7	62.6
	97.5	101	77.6	56.8	62.1
Per share
	₹30.06	₹31.30	₹24.04	₹17.90	₹19.78
	₹29.65	₹30.88	₹23.56	₹17.31	₹19.29
Other comprehensive income — detail
	0.2	0.2	0.5	—	—
	0.2	0.3	0.6	−0.2	0.7
	0.1	0.1	0.1	—	—
	—	—	—	−0.0	0.2
	97.7	102	78.1	56.7	62.6
Per share — as-filed variants
	₹30.06	₹31.30	₹24.04	₹17.90	₹19.78
	₹29.65	₹30.88	₹23.56	₹17.31	₹19.29
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	634	594	548	479	413
	77.7%	76.8%	76.4%	77.2%	84.8%
Adjusted (ex-exceptional items) — derived
	125	130	103	70.0	80.2
	97.5	101	77.6	56.8	62.1
	₹30.06	₹31.30	₹24.04	₹17.90	₹19.78

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSURAKSHA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,615 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	487.1	619.6	717.2	772.8	815.3
Other Income	19.4	16.8	25.5	43.4	46.7
Total Income	506.5	636.4	742.7	816.2	862.0
Expenses
+ Cost of Materials Consumed	74.2	141.0	169.3	179.0	181.8
+ Employee Benefit Expense	74.6	111.5	136.8	140.5	141.0
+ Finance Costs	7.7	16.5	24.7	34.4	42.9
+ Depreciation & Amortisation	53.8	74.5	88.3	90.5	96.8
+ Other Expenses	216.1	222.9	221.0	241.4	274.1
Total Expenses	426.3	566.4	640.0	685.7	736.6
EBITDA	122.3	144.2	190.1	211.9	218.5
EBIT	68.5	69.7	101.8	121.4	121.7
Profit
PBT before Exceptional Items	80.2	70.0	102.7	130.4	125.5
Pretax Income	80.2	70.0	102.7	130.4	125.5
+ Current Tax	15.0	10.8	21.8	24.4	24.4
+ Deferred Tax	3.1	2.4	3.3	4.5	3.6
Tax Expense	18.1	13.2	25.1	28.9	27.9
+ Share of Associates & JVs	0.0	0.0	0.0	-0.1	-0.1
Net Income	62.1	56.8	77.6	101.4	97.5
+ Net Income — Continuing Ops	62.1	56.8	77.6	101.5	97.5
+ Other Comprehensive Income	0.5	-0.1	0.5	0.2	0.2
Total Comprehensive Income	62.6	56.7	78.1	101.6	97.6
Net Income to Common	62.1	56.8	77.6	101.4	97.5
Per Share
Basic EPS	19.78	17.90	24.04	31.30	30.06
Diluted EPS	19.29	17.31	23.56	30.88	29.65
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.5	0.2	0.2
+ Items NOT to be Reclassified to P&L	0.7	-0.2	0.6	0.3	0.2
+ Tax on Items NOT to be Reclassified	—	—	0.1	0.1	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.2	-0.0	—	—	—
Comprehensive Income — Owners of Parent	62.6	56.7	78.1	101.6	97.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	19.78	17.90	24.04	31.30	30.06
Diluted EPS — Continuing Operations	19.29	17.31	23.56	30.88	29.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	412.9	478.6	547.9	593.7	633.5
Gross Margin %	84.77	77.24	76.40	76.83	77.70
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	80.2	70.0	102.7	130.4	125.5
Net Income Adj (tax-effected)	62.1	56.8	77.6	101.4	97.5
EPS Adj	19.78	17.90	24.04	31.30	30.06
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Filed Debt Equity	—	—	—	0.53	—
Filed Dscr	—	—	—	2.81	—
Paid Up Equity Capital	15.7	16.1	16.1	16.2	16.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.